Xenon Pharmaceuticals
XENE
17 hedge funds and large institutions have $83.1M invested in Xenon Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$9.68M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$9.08M |
| 4 |
VAM
Visium Asset Management
New York
|
+$6.61M |
| 5 |
IPC
Invesco Private Capital
New York
|
+$6.53M |
Top Sellers
XENE Hedge Fund Activity: Q4 2014 in Review
17 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2014, worth a combined $83.1M.
Buyers outnumbered sellers: 17 funds opened new XENE positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $18.4M.
- 17 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $83.1M of Xenon Pharmaceuticals stock for Q4 2014.
- 17 funds opened new Xenon Pharmaceuticals positions in Q4 2014 and 0 closed out, a net change of +17 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2014 was Fidelity Investments, an estimated $18.4M added.
Based on aggregated 13F filings for Q4 2014.